NanoViricides' NV-387 Eyed for Ebola Outbreak Response

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has announced that its broad-spectrum antiviral candidate NV-387 warrants evaluation as a potential treatment option for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa. The company highlights the absence of approved vaccines or therapies specifically targeting this virus strain, underscoring the urgent need for effective interventions. NV-387’s host-targeted antiviral mechanism and oral formulation could offer significant advantages in outbreak settings, where treatment delivery and healthcare worker safety are critical. Notably, the drug is already being prepared for a Phase II clinical trial in the Democratic Republic of Congo for mpox, which could support near-term regional availability if found effective against Ebola.

NanoViricides is a clinical-stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral designed to treat RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. The company also has other advanced drug candidates, including NV-HHV-1 for Shingles. The company’s nanoviricide technology is based on intellectual property from TheraCour Pharma, Inc., and NanoViricides holds exclusive licenses for several human viral diseases. The company is currently focused on advancing NV-387 into Phase II human clinical trials.

Beyond Ebola, NanoViricides is developing drugs against a range of viral diseases, including herpes, influenza, HIV, Hepatitis C, Rabies, Dengue fever, and more. The company’s platform technology and programs are based on the TheraCour® nanomedicine technology. For investors, the latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC. The full press release can be accessed at https://ibn.fm/aSF5Z.